Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America ...

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development Lonza unveils its "One Lonza" strategy, highlighting a new structure to streamline operations ...

Lonza Group AG's (VTX:LONN) earnings announcement last week didn't impress shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the ...

How Lonza Capsules & Health Ingredients (CHI) is redefining drug delivery with cutting-edge capsule innovation, ...

In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price ...

Here is how Bayer Aktiengesellschaft (BAYRY) and Lonza Group Ag (LZAGY) have performed compared to their sector so far this year. Lonza Group (LZAGY) might move higher on growing optimism about its ...

Earnings Estimate Revisions for Lonza Group For the fiscal year ending December 2025, this company is expected to earn $1.87 per share, which is a change of 9.4% from the year-ago reported number. ...